Shares of Masimo Corp. MASI scaled a new 52-week high of $60.05 on Sep 19. This translates into an impressive year-to-date return of roughly 44.2%, which is significantly higher than the S&P 500 return of 4.7%.
This Zacks Rank #1 (Strong Buy) stock has a market cap of around $2.93 billion while the average volume of shares traded over the last three months is roughly 299.1K.
Key Growth Factors
We believe that Masimo's expanding product portfolio is its key catalyst. Wider adoption of non-invasive patient monitoring technology is helping the company to gain market share. Also, Masimo’s SET pulse oximetry business has considerable growth opportunities in international markets. Moreover, the recent FDA 510 (k) approvals for the Radius 7 wearable and the O3 regional oximetry device are its other positives.
This manufacturer of non-invasive monitoring technologies is currently riding on robust business. Last month, the company reported impressive second-quarter 2016 results and projected higher total revenue and earnings for the full year. These developments continue to bode well for the company, as reflected by the new high.
For 2016, Masimo projects total revenue of $689 million, up from the previous projection of $677 million. Product revenues are expected at around $658 million, up from the previous guidance of $647 million. Meanwhile, Royalty revenue is expected at $31 million, up from the previously guided $30 million.
Masimo forecasts gross margin of approximately 65%, up from 64.7% guided previously. Management expects operating expense of approximately $314 million, which is also slightly higher than the previous guidance of $312 million. Masimo projects earnings of $2.01 per share, up from the previously projected figure of $1.83.
Other Stocks to Consider
Other favorably ranked stocks in the medical space are GW Pharmaceuticals plc GWPH, NuVasive, Inc. NUVA and Baxter International Inc. BAX. Each of these stocks sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research